A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome
Angelman syndrome is a rare genetic condition that affects the nervous system, causing severe learning difficulties, speech problems, and movement challenges. Currently, there is no cure, and treatments only manage symptoms. This Phase 3 trial looks at an experimental medicine called GTX-102. Researchers want to find out whether GTX-102 is safe and works well for children with Angelman syndrome. To test this fairly, half the children receive the real medicine and the other half receive a dummy treatment (a sham procedure) so results can be compared without bias. Over roughly 11 months (about 338 days), doctors will track changes in thinking skills, speech, motor coordination, and sleep patterns. They will also watch closely for any side effects. The goal is to see if GTX-102 can genuinely improve everyday abilities and quality of life.
At a glance
What is this study about?
Angelman syndrome is a rare condition that affects a child's development. It is caused by a problem with a specific gene in the brain. Children with Angelman syndrome usually have severe delays in learning, struggle with balance and walking, find speech very difficult, and often have trouble sleeping. At the moment, there are no approved medicines that treat the root cause of the condition.
This study tests an investigational medicine called GTX-102. Scientists designed GTX-102 to help activate a dormant copy of the missing gene in the brain. By helping the brain produce the protein it needs, researchers hope this medicine might improve day-to-day skills, communication, and behaviour in children living with the condition.
Because this is a Phase 3 study, it is one of the final stages of testing before a new medicine can be approved for general use. The trial is 'double-blind' and 'sham-controlled', meaning neither the families nor the assessing doctors will know who gets the real medicine and who gets a dummy procedure. This is the gold standard way to make sure the findings are completely reliable.
Key takeaways
- Phase 3 trial testing GTX-102 for children with Angelman syndrome.
- Compares the study drug to a dummy procedure over about 11 months.
- Checks for improvements in learning, speech, movement, and sleep.
- Neither families nor doctors know who gets the real drug during the study.
- Participation is voluntary and close medical monitoring is provided throughout.
Who may be eligible?
This trial is designed specifically for children who have a confirmed diagnosis of Angelman syndrome. Both boys and girls can join.
Because this is a paediatric trial, children must be within a specific age range set by the study team. They will also need to be well enough to undergo the study assessments and procedures safely.
Children with certain other health conditions, recent changes in medication, or past treatments that could interfere with the study results may not be eligible to participate. A full medical check-up will confirm if your child qualifies.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- My child has a confirmed medical diagnosis of Angelman syndrome.
- My child falls within the paediatric age range required for the trial.
- We can attend regular hospital visits for assessments over roughly 11 months.
- My child does not have other serious medical issues that would make taking part unsafe.
- I am willing for my child to potentially receive a dummy (sham) treatment.
What does participation involve?
Taking part lasts around 11 months (up to Day 338), with possible follow-up visits afterwards. Children will be randomly placed into one of two groups: one group receives GTX-102, and the other receives a dummy treatment. Because the medicine is given by an injection, children having the dummy treatment will receive a 'sham' procedure so it looks and feels identical.
Families will need to attend regular clinic visits. At these visits, the study team will test your child's thinking, communication, and movement skills using play-based activities and developmental scales. Doctors will also track sleep, monitor daily behaviours, and check blood samples and heart rhythms to ensure your child remains safe throughout.
Potential risks and benefits
Locations (4)
- —UnverifiedNetherlands
- —UnverifiedSpain
- —UnverifiedGermany
- —UnverifiedPoland
Common questions
What is a sham procedure?
A sham procedure is a dummy process designed to look and feel like the real treatment. It ensures that neither you nor the doctors know who is getting the real medicine, keeping the study fair and unbiased.
Will taking part cost anything?
No, the study medicine and all related tests are provided free of charge. Most trials also help cover reasonable travel and accommodation costs for hospital visits.
Can my child stay on their usual medicines?
In many cases, yes, but the study doctor will check all your child's regular medicines to ensure they are safe to use alongside the study treatment.
What happens if my child feels unwell during the trial?
The research team is on hand to help. If your child becomes unwell, doctors will assess them immediately and provide appropriate medical treatment.
Can we drop out if we change our mind?
Yes. You have the right to withdraw your child from the study at any point without giving a reason, and your regular care will carry on as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.